ClinicalTrials.gg
TerminatedNCT01764997RA-COMPAREUpdated Jul 27, 2017Results posted

An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate

A Phase 3 interventional study of Sarilumab and Etanercept in Rheumatoid Arthritis, sponsored by Sanofi. Terminated at 257 sites in 31 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-27.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to small number of participants entering randomization. Not a safety issue.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
776
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 22 studies testing sarilumab in Arthritis, Rheumatoid — 2 open to participants now, 2 under way, 1 of them phase 3. sarilumab · Arthritis, Rheumatoid.

Enrollment
3rd of 22
776 · median 88
Started
2013
with 1 other
Phase 3
9 of 22
1 open now
Registered
9th of 22
by date
Lead sponsor
14 of 22
Sanofi

Among the 22 studies testing sarilumab in Arthritis, Rheumatoid, this one is the 3rd largest by enrollment, is one of 2 that started in 2013, is one of 9 in phase 3, and was the 9th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 22 studies testing sarilumab in Arthritis, Rheumatoid are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About sarilumab

sarilumab: first FDA approval 2017 (KEVZARA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing sarilumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the treatment effect of sarilumab and methotrexate (MTX) compared to etanercept and MTX in participants with rheumatoid arthritis (RA) and an inadequate response to adalimumab and MTX by evaluation of the Disease Activity Score for 28 joints (DAS28).

Secondary Objectives:

To assess the signs and symptoms of RA in participants taking sarilumab in combination with MTX.

To assess the quality of life of participants with RA taking sarilumab in combination with MTX.

To assess the safety and tolerability of sarilumab in combination with MTX in participants with RA.

Read the detailed description

The maximum study duration per participant enrolled in the open label run-in phase and was eligible to enroll in the randomized phase of main study was 54 weeks:

  • open label screening period of up to 4 weeks
  • open-label treatment period of 16 weeks
  • randomized screening period of 2 to 4 weeks
  • randomized treatment post-treatment safety follow-up period of 6 weeks.

The maximum study duration per participant enrolled only in the open label run-in phase and was not eligible to enroll in the randomized phase of main study was 26 weeks:

  • open label screening period of up to 4 weeks
  • open-label treatment period of 16 weeks
  • open label treatment post-treatment safety follow-up period of 6 weeks.

The maximum study duration per participant enrolled in the open label run-in phase and was eligible to enroll in the sarilumab sub-study was 82 weeks:

  • open label screening period of up to 4 weeks
  • open-label treatment period of 16 weeks
  • screening period of 2 to 4 weeks
  • sarilumab treatment period of 52 weeks
  • sub-study post-treatment safety follow-up period of 6 weeks.
03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of RA >/= 3 months duration.
  • Continuous treatment of MTX 10 - 25 mg/week (or per local labeling requirements if the dose range differs) for at least 12 weeks before screening visit and on a stable dose for 8 weeks before screening visit.
  • Active disease defined as: at least 6/66 swollen and 8/68 tender joints and high sensitivity C-reactive protein > 10 mg/L.

Exclusion criteria

Exclusion criteria:

  • Age \< 18 years.
  • Use of parenteral or intra-articular corticosteroids within 4 weeks of the screening visit.
  • Use of oral corticosteroids in a dose higher than prednisone 10 mg or equivalent per day, or a change in dosage within 4 weeks of the screening visit.
  • Prior treatment with a tumor necrosis factor (TNF)-alpha inhibitor, or other biological disease modifying anti-rheumatoid drug (DMARD) or Janus Kinase inhibitor.
  • New treatment with or dose-adjustment of on-going nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclo-oxygenase-2 (COX-2) inhibitors within 4 weeks of the screening visit.
  • Treatment with traditional oral DMARD / agents other than MTX within 4 weeks or 12 weeks before the screening visit, depending on DMARD.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
776 participants (actual)

Study arms

  • Experimental
    Adalimumab Open Label run-in

    Adalimumab 40 mg every 2 weeks (Q2W) for 16 weeks added to stable dose of MTX.

    Drug: Methotrexate · Drug: Adalimumab

  • Active comparator
    Etanercept + MTX (Randomized)

    Etanercept 50 mg in combination with Placebo for sarilumab Q2W and etanercept 50 mg on alternating weeks for 24 weeks added to stable dose of MTX.

    Drug: Etanercept · Drug: Methotrexate · Drug: Placebo (for sarilumab)

  • Experimental
    Sarilumab 150 mg + MTX (Randomized)

    Sarilumab 150 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.

    Drug: Sarilumab · Drug: Methotrexate · Drug: Placebo (for etanercept)

  • Experimental
    Sarilumab 200 mg + MTX (Randomized)

    Sarilumab 200 mg in combination with placebo for etanercept Q2W and placebo for etanercept on alternating weeks for 24 weeks added to stable dose of MTX.

    Drug: Sarilumab · Drug: Methotrexate · Drug: Placebo (for etanercept)

  • Experimental
    Sarilumab 150 mg + MTX Open Label Sub-study

    Sarilumab 150 mg Q2W for 52 weeks added to stable dose of MTX.

    Drug: Sarilumab · Drug: Methotrexate

Interventions

  • Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous

    Also known as: SAR153191, REGN88

  • Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous

    Also known as: Enbrel

  • Dispensed according to local practice.

  • DrugPlacebo (for sarilumab)
  • DrugPlacebo (for etanercept)
  • Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score for 28 Joints - C-Reactive Protein (DAS28-CRP) Score at Week 24

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Number of Participants With at Least 20% Improvement in American College of Rheumatology (ACR20), at Least 50% Improvement in ACR (ACR50) and at Least 70% Improvement in ACR (ACR70) Efficacy Response Rates at Week 12 and Week 24

    Time frame: Week 12 and Week 24

  2. Percentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 12 and Week 24

    Time frame: Week 12 and Week 24

  3. Change From Baseline in DAS28-CRP Score at Week 12

    Time frame: Baseline, Week 12

07

Results

Posted Jul 27, 2017
Limitations and caveats
The study was prematurely terminated due to small number of participants entering randomization.

Participant flow

The study was conducted at 228 sites in 31 countries. A total of 1949 participants were screened between 09 May 2013 and 07 Aug 2014 of which 1173 participants were screen failures and a total of 776 participants entered in the adalimumab run-in phase of the study.

Run-in Period
Participant flow — Run-in Period
MilestoneAdalimumab Open Label run-inEtanercept + MTX (Randomized)Sarilumab 150 mg + MTX (Randomized)Sarilumab 200 mg + MTX (Randomized)Sarilumab 150 mg + MTX Open Label Sub-study
Started7760000
Completed7380000
Not completed380000
Withdrew: Adverse event150000
Withdrew: Lack of efficacy50000
Withdrew: Poor compliance to protocol10000
Withdrew: Other than specified above170000
Study Drug Treatment Period
Participant flow — Study Drug Treatment Period
MilestoneAdalimumab Open Label run-inEtanercept + MTX (Randomized)Sarilumab 150 mg + MTX (Randomized)Sarilumab 200 mg + MTX (Randomized)Sarilumab 150 mg + MTX Open Label Sub-study
Started0171313322
Completed0161313286
Not completed010036
Withdrew: Adverse event010024
Withdrew: Lack of efficacy00002
Withdrew: Other than specified above000010

Outcome measures

PrimaryChange From Baseline in Disease Activity Score for 28 Joints - C-Reactive Protein (DAS28-CRP) Score at Week 24
Time frame:
Baseline, Week 24

No measurements were reported for this outcome.

SecondaryNumber of Participants With at Least 20% Improvement in American College of Rheumatology (ACR20), at Least 50% Improvement in ACR (ACR50) and at Least 70% Improvement in ACR (ACR70) Efficacy Response Rates at Week 12 and Week 24
Time frame:
Week 12 and Week 24

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving Clinical Remission Score (DAS28-CRP) <2.6 at Week 12 and Week 24
Time frame:
Week 12 and Week 24

No measurements were reported for this outcome.

SecondaryChange From Baseline in DAS28-CRP Score at Week 12
Time frame:
Baseline, Week 12

No measurements were reported for this outcome.

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 16 for run-in period and Week 58 for treatment period) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab Open Label run-in—25/776 (3.2%)132/776 (17%)
Etanercept + MTX (Randomized)—2/17 (11.8%)7/17 (41.2%)
Sarilumab 150 mg + MTX (Randomized)—0/13 (0%)7/13 (53.8%)
Sarilumab 200 mg + MTX (Randomized)—0/13 (0%)8/13 (61.5%)
Sarilumab 150 mg + MTX Open Label Sub-study—11/322 (3.4%)104/322 (32.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventAdalimumab Open Label run-inEtanercept + MTX (Randomized)Sarilumab 150 mg + MTX (Randomized)Sarilumab 200 mg + MTX (Randomized)Sarilumab 150 mg + MTX Open Label Sub-study
Urinary tract infectionInfections and infestations0/7761/170/130/130/322
Hypersensitivity vasculitisSkin and subcutaneous tissue disorders0/7761/170/130/130/322
Colonic abscessInfections and infestations0/7760/170/130/131/322
DiverticulitisInfections and infestations1/7760/170/130/131/322
Escherichia pyelonephritisInfections and infestations0/7760/170/130/131/322
Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7760/170/130/131/322
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7760/170/130/131/322
Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7760/170/130/131/322
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/7760/170/130/131/322
NeutropeniaBlood and lymphatic system disorders0/7760/170/130/131/322
Most frequent other events
Showing 10 of 47
Most frequent other events
EventAdalimumab Open Label run-inEtanercept + MTX (Randomized)Sarilumab 150 mg + MTX (Randomized)Sarilumab 200 mg + MTX (Randomized)Sarilumab 150 mg + MTX Open Label Sub-study
Accidental overdoseInjury, poisoning and procedural complications24/7760/173/130/1314/322
NeutropeniaBlood and lymphatic system disorders2/7761/171/132/1333/322
Alanine aminotransferase increasedInvestigations5/7760/170/132/1311/322
Body tineaInfections and infestations1/7760/170/131/130/322
HordeolumInfections and infestations2/7760/171/130/130/322
OnychomycosisInfections and infestations0/7760/170/131/130/322
PharyngitisInfections and infestations7/7760/170/131/133/322
Pharyngitis streptococcalInfections and infestations0/7760/171/130/130/322
Rash pustularInfections and infestations1/7760/171/130/130/322
SinusitisInfections and infestations7/7760/170/131/135/322

Baseline characteristics

All participants who included in open label run-in period, randomized treatment and sub-study.

Age, Categorical
Age, Categorical(Participants)Adalimumab Open Label run-in Treatment OnlyEtanercept + MTX (Randomized)Sarilumab 150 mg + MTX (Randomized)Sarilumab 200 mg + MTX (Randomized)Sarilumab 150 mg + MTX Open Label Sub-studyTotal
<=18 years000000
Between 18 and 65 years360141010274668
>=65 years5133348108
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab Open Label run-in Treatment OnlyEtanercept + MTX (Randomized)Sarilumab 150 mg + MTX (Randomized)Sarilumab 200 mg + MTX (Randomized)Sarilumab 150 mg + MTX Open Label Sub-studyTotal
Female34215109261637
Male6923461139
08

Study locations

257 sites
  • Investigational Site Number 840004
    Birmingham, Alabama 35205, United States
  • Investigational Site Number 840212
    Glendale, California 91205, United States
  • Investigational Site Number 840211
    Thousand Oaks, California 91360, United States
  • Investigational Site Number 840049
    Upland, California 91786, United States
  • Investigational Site Number 840205
    Victorville, California 92395, United States
  • Investigational Site Number 840201
    Denver, Colorado 80230, United States
  • Investigational Site Number 840209
    Danbury, Connecticut 06810, United States
  • Investigational Site Number 840203
    Washington, D.C., District of Columbia 20003, United States
  • Investigational Site Number 840210
    Clearwater, Florida 33756, United States
  • Investigational Site Number 840128
    Ormond Beach, Florida 32174, United States
  • Investigational Site Number 840063
    Palm Harbor, Florida 34684, United States
  • Investigational Site Number 840060
    Sarasota, Florida 34239, United States
  • Investigational Site Number 840207
    Tampa, Florida 33612, United States
  • Investigational Site Number 840018
    Idaho Falls, Idaho 83404, United States
  • Investigational Site Number 840213
    Indianapolis, Indiana 46250, United States
  • Investigational Site Number 840109
    Lake Charles, Louisiana 70601, United States
  • Investigational Site Number 840073
    Cumberland, Maryland 21502, United States
  • Investigational Site Number 840202
    Hagerstown, Maryland 21740, United States
  • Investigational Site Number 840204
    Battle Creek, Michigan 49015, United States
  • Investigational Site Number 840150
    Lansing, Michigan 48910, United States
  • Investigational Site Number 840200
    Jackson, Mississippi 39216, United States
  • Investigational Site Number 840037
    Tupelo, Mississippi 38801, United States
  • Investigational Site Number 840112
    Lincoln, Nebraska 68516, United States
  • Investigational Site Number 840056
    New York, New York 10016, United States
  • Investigational Site Number 840117
    Pittsburgh, Pennsylvania 15261, United States
  • Investigational Site Number 840016
    North Charleston, South Carolina 29406, United States
  • Investigational Site Number 840025
    Jackson, Tennessee 38305, United States
  • Investigational Site Number 840074
    Mesquite, Texas 75150, United States
  • Investigational Site Number 840061
    Tacoma, Washington 98405, United States
  • Investigational Site Number 840124
    Clarksburg, West Virginia 26301, United States
  • Investigational Site Number 032052
    Buenos Aires, C1015ABO, Argentina
  • Investigational Site Number 032050
    Buenos Aires, C1426AAL, Argentina
  • Investigational Site Number 032053
    La Plata, Argentina
  • Investigational Site Number 032013
    Rosario, S200PBJ, Argentina
  • Investigational Site Number 032051
    San Miguel De Tucumán, Argentina
  • Investigational Site Number 032005
    Tucuman, 4000, Argentina
  • Investigational Site Number 032009
    Zarate, B2800DGH, Argentina
  • Investigational Site Number 036020
    Camperdown, 2050, Australia
  • Investigational Site Number 036004
    Heidelberg West, 3081, Australia
  • Investigational Site Number 036014
    Victoria Park, 6100, Australia
  • Investigational Site Number 036007
    Woodville, 5011, Australia
  • Investigational Site Number 076001
    Curitiba, 80060-240, Brazil
  • Investigational Site Number 076016
    Curitiba, Brazil
  • Investigational Site Number 076006
    Goiania, 74110-120, Brazil
  • Investigational Site Number 076010
    Juiz De Fora, 36010-570, Brazil
  • Investigational Site Number 076005
    Rio De Janeiro, 20551-030, Brazil
  • Investigational Site Number 076013
    Vitoria, 29055 450, Brazil
  • Investigational Site Number 152005
    Osorno, 5311092, Chile
  • Investigational Site Number 152018
    Santiago, 7510047, Chile
  • Investigational Site Number 152001
    Santiago, Chile
  • Investigational Site Number 152002
    Santiago, Chile
  • Investigational Site Number 152011
    Santiago, Chile
  • Investigational Site Number 152015
    Temuco, Chile
  • Investigational Site Number 170016
    Bogota, 0, Colombia
  • Investigational Site Number 170001
    Bogota, Colombia
  • Investigational Site Number 170040
    Bogotá, NAP, Colombia
  • Investigational Site Number 170007
    Bucaramanga, Colombia
  • Investigational Site Number 170009
    Bucaramanga, Colombia
  • Investigational Site Number 170041
    Medellin, Colombia
  • Investigational Site Number 203004
    Ostrava, 702 00, Czechia
  • Investigational Site Number 203001
    Praha 2, 12850, Czechia
  • Investigational Site Number 203031
    Praha 4, 14059, Czechia
  • Investigational Site Number 203033
    Praha 4, 14800, Czechia
  • Investigational Site Number 203030
    Praha 4, Czechia
  • Investigational Site Number 203032
    Praha, 11000, Czechia
  • Investigational Site Number 203002
    Uherske Hradiste, 686 01, Czechia
  • Investigational Site Number 203006
    Zlin, 76001, Czechia
  • Investigational Site Number 218003
    Cuenca, Ecuador
  • Investigational Site Number 218001
    Guayaquil, 0593, Ecuador
  • Investigational Site Number 218002
    Quito, 0593, Ecuador
  • Investigational Site Number 246001
    Helsinki, 00290, Finland
  • Investigational Site Number 246002
    Hyvinkää, 05800, Finland
  • Investigational Site Number 246030
    Oulu, 90100, Finland
  • Investigational Site Number 246003
    Pori, 28100, Finland
  • Investigational Site Number 246032
    Tampere, Finland
  • Investigational Site Number 250003
    Amiens Cedex 1, 80054, France
  • Investigational Site Number 250007
    Bobigny, France
  • Investigational Site Number 250001
    La Roche Sur Yon Cedex 9, 85925, France
  • Investigational Site Number 250002
    Montpellier, 34295, France
  • Investigational Site Number 250004
    Paris Cedex 4, 75181, France
  • Investigational Site Number 250005
    Paris, 74014, France
  • Investigational Site Number 250006
    Strasbourg, France
  • Investigational Site Number 250008
    Toulouse, 31000, France
  • Investigational Site Number 276007
    Berlin, 12161, Germany
  • Investigational Site Number 276057
    Berlin, 12161, Germany
  • Investigational Site Number 276056
    Dresden, 01109, Germany
  • Investigational Site Number 276055
    Dresden, 01307, Germany
  • Investigational Site Number 276051
    Erlangen, 91056, Germany
  • Investigational Site Number 276013
    Hamburg, 22147, Germany
  • Investigational Site Number 276001
    Herne, 44649, Germany
  • Investigational Site Number 276058
    Koeln, Germany
  • Investigational Site Number 276053
    Ludwigsfelde, 14974, Germany
  • Investigational Site Number 276050
    Rostock, Germany
  • Investigational Site Number 300010
    Athens, 11527, Greece
  • Investigational Site Number 300002
    Heraklion, 71110, Greece
  • Investigational Site Number 300014
    N. Efkarpia, 56429, Greece
  • Investigational Site Number 300012
    Patras, Greece
  • Investigational Site Number 348001
    Budapest, 1023, Hungary
  • Investigational Site Number 348010
    Debrecen, 4031, Hungary
  • Investigational Site Number 348021
    Esztergom, 2500, Hungary

Showing the first 100 of 257 sites across 31 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2013, a primary completion of Jan 2015 and a completion of Jan 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2017, 2 years 6 months after primary completion. A results delay was requested in Oct 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2013
First posted
Jan 10, 2013
Start
Apr 2013
Primary completionActual
Jan 2015
CompletionActual
Jan 2015
Results delay requested
Oct 7, 2015
Results first posted
Jul 27, 2017
Last update
Jul 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01764997
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 10, 2013
Start date
Apr 2013
Primary completion
Jan 2015
Completion
Jan 2015
Results posted
Jul 27, 2017
Last update
Jul 27, 2017

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sarilumab · Adalimumab

Start the discussion